Would Cortisol Measurements Be a Better Gauge of Hydrocortisone Replacement Therapy? Congenital Adrenal Hyperplasia As an Exemplar

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2020 Dec 10

PMID 33299411

Authors

Peter C Hindmarsh

John W Honour

Affiliations

Soon will be listed here.

Abstract

There is an increase in mortality and morbidity as well as poor quality of life in patients with congenital adrenal hyperplasia (CAH) and other causes of adrenal insufficiency. Glucocorticoid replacement therapy should aim to replace the missing cortisol as close as possible to the normal circadian rhythm using hydrocortisone. Dosing should be based on the individual's absorption and clearance of the drug. Adequacy of dosing should be checked using 24-hour profiles of plasma cortisol with samples drawn preferably every hour or at least every 2 hours. Measurement of cortisol should be the preferred method of assessing replacement therapy as it is over- and undertreatment with hydrocortisone, both of which can occur over a 24-hour period, which leads to the problems observed in patients with CAH and adrenal insufficiency.

References

Van Cauter E, Leproult R, Kupfer D . Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996; 81(7):2468-73. DOI: 10.1210/jcem.81.7.8675562. View

Arlt W, Willis D, Wild S, Krone N, Doherty E, Hahner S . Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab. 2010; 95(11):5110-21. PMC: 3066446. DOI: 10.1210/jc.2010-0917. View

Frisch H, Parth K, Schober E, Swoboda W . Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia. Arch Dis Child. 1981; 56(3):208-13. PMC: 1627169. DOI: 10.1136/adc.56.3.208. View

Guignard M, Pesquies P, Serrurier B, Merino D, Reinberg A . Circadian rhythms in plasma levels of cortisol, dehydroepiandrosterone, delta 4-androstenedione, testosterone and dihydrotestosterone of healthy young men. Acta Endocrinol (Copenh). 1980; 94(4):536-45. DOI: 10.1530/acta.0.0940536. View

Dennison E, Hindmarsh P, Fall C, Kellingray S, Barker D, Phillips D . Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab. 1999; 84(9):3058-63. DOI: 10.1210/jcem.84.9.5964. View

Falhammar H, Thoren M . Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine. 2012; 41(3):355-73. DOI: 10.1007/s12020-011-9591-x. View

KENNY F, Malvaux P, Migeon C . Cortisol production rate in newborn babies, older infants, and children. Pediatrics. 1963; 31:360-73. View

Debono M, Ross R . What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012?. Clin Endocrinol (Oxf). 2012; 78(5):659-64. DOI: 10.1111/cen.12117. View

Swerdlow A, Higgins C, Brook C, Dunger D, Hindmarsh P, Price D . Mortality in patients with congenital adrenal hyperplasia: a cohort study. J Pediatr. 1998; 133(4):516-20. DOI: 10.1016/s0022-3476(98)70060-5. View

10.

Peters C, Hill N, Dattani M, Charmandari E, Matthews D, Hindmarsh P . Deconvolution analysis of 24-h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 2012; 78(3):347-51. DOI: 10.1111/j.1365-2265.2012.04502.x. View

11.

Filipsson H, Monson J, Koltowska-Haggstrom M, Mattsson A, Johannsson G . The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006; 91(10):3954-61. DOI: 10.1210/jc.2006-0524. View

12.

Melin J, Parra-Guillen Z, Michelet R, Truong T, Huisinga W, Hartung N . Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2020; 105(3). DOI: 10.1210/clinem/dgaa071. View

13.

Burman P, Mattsson A, Johannsson G, Hoybye C, Holmer H, Dahlqvist P . Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013; 98(4):1466-75. DOI: 10.1210/jc.2012-4059. View

14.

Charmandari E, Hindmarsh P, Johnston A, Brook C . Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab. 2001; 86(6):2701-8. DOI: 10.1210/jcem.86.6.7522. View

15.

Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G . Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab. 2006; 91(12):4849-53. DOI: 10.1210/jc.2006-0076. View

16.

Subbarayan A, Dattani M, Peters C, Hindmarsh P . Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf). 2013; 80(4):471-7. PMC: 4204515. DOI: 10.1111/cen.12265. View

17.

Finkielstain G, Kim M, Sinaii N, Nishitani M, Van Ryzin C, Hill S . Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012; 97(12):4429-38. PMC: 3513542. DOI: 10.1210/jc.2012-2102. View

18.

Hindmarsh P . Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab. 2009; 23(2):193-208. DOI: 10.1016/j.beem.2008.10.010. View

19.

Hartmann A, Veldhuis J, Deuschle M, Standhardt H, Heuser I . Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997; 18(3):285-9. DOI: 10.1016/s0197-4580(97)80309-0. View

20.

Hindmarsh P, Charmandari E . Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. Clin Endocrinol (Oxf). 2014; 82(4):557-61. DOI: 10.1111/cen.12653. View